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Abstract
Vitamin D deficiency has been associated with several common diseases, including cancer and is being investigated as a
possible risk factor for these conditions. We reported the striking prevalence of vitamin D deficiency in Scotland. Previous
epidemiological studies have reported an association between low dietary vitamin D and colorectal cancer (CRC). Using a
case-control study design, we tested the association between plasma 25-hydroxy-vitamin D (25-OHD) and CRC (2,001 cases,
2,237 controls). To determine whether plasma 25-OHD levels are causally linked to CRC risk, we applied the control function
instrumental variable (IV) method of the Mendelian randomization (MR) approach using four single nucleotide
polymorphisms (rs2282679, rs12785878, rs10741657, rs6013897) previously shown to be associated with plasma 25-OHD.
Low plasma 25-OHD levels were associated with CRC risk in the crude model (odds ratio (OR): 0.76, 95% Confidence Interval
(CI): 0.71, 0.81, p: 1.4610
214) and after adjusting for age, sex and other confounding factors. Using an allele score that
combined all four SNPs as the IV, the estimated causal effect was OR 1.16 (95% CI 0.60, 2.23), whilst it was 0.94 (95% CI 0.46,
1.91) and 0.93 (0.53, 1.63) when using an upstream (rs12785878, rs10741657) and a downstream allele score (rs2282679,
rs6013897), respectively. 25-OHD levels were inversely associated with CRC risk, in agreement with recent meta-analyses.
The fact that this finding was not replicated when the MR approach was employed might be due to weak instruments,
giving low power to demonstrate an effect (,0.35). The prevalence and degree of vitamin D deficiency amongst individuals
living in northerly latitudes is of considerable importance because of its relationship to disease. To elucidate the effect of
vitamin D on CRC cancer risk, additional large studies of vitamin D and CRC risk are required and/or the application of
alternative methods that are less sensitive to weak instrument restrictions.
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Introduction
Vitamin D can be ingested or synthesized in the skin from
inactive precursors through the action of UV sunlight. Its active
form, 1,25(OH)2D (1,25(OH)2D2 and/or 1,25(OH)2D3) is pro-
duced after two hydroxylation steps in the liver and kidneys
(Figure 1) [1]. The prevalence of vitamin D deficiency in
Scotland is high due to high northern latitude, often cloudy
weather (lack of sunlight impairs vitamin D synthesis during winter
months), indoors oriented lifestyle and poor diet, and so routine
vitamin D and calcium supplementation for the housebound (.65
years old) is recommended [2]. In a recent study of over 2000
healthy individuals living in Scotland, we found that 77.5% of the
individuals were vitamin D deficient [3]. Although the Reference
Nutrient Intake (RNI) of vitamin D by the Scientific Advisory
Committee on Nutrition in Scotland for people over 65 years old is
10 ug per day [4], there is a great variation of the recommended
daily allowances (RDA) by different research groups and
institutions [5–8].
Vitamin D has been considered relevant to skeletal disease and
calcium metabolism, but there is growing evidence that vitamin D
deficiency might be a risk factor for cancer, cardiovascular,
metabolic, infectious and autoimmune diseases [3]. In particular,
vitamin D may affect colorectal cancer (CRC) risk via its binding
to the vitamin D receptor (VDR) [9] influencing cell proliferation,
differentiation, apoptosis and angiogenesis [10,11] or affecting
insulin resistance [12]. Results from case-control and cohort
studies are inconclusive, but results from cohort studies measuring
25-hydroxy-vitamin D (25-OHD) in the blood or the serum are
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15].
Establishing causal relationships between environmental expo-
sures and common diseases using conventional methods of
observational studies is problematic due to unresolved confound-
ing, reverse causation and selection bias [16]. The theory
underpinning the Mendelian randomization (MR) approach is
based on the random assortment of alleles at the time of gamete
formation, which is equivalent to a randomized controlled trial in
which people are randomly allocated to therapeutic interventions.
The main concept of a MR study is based on three relationships:
genotype–intermediate phenotype; intermediate phenotype–dis-
ease; genotype–disease [17,18] and it can be used to identify causal
environmental risk factors without the several potential problems
of observational epidemiology [19]. The MR approach can also
strengthen causal conclusions by limiting reverse causation
problems (biological, through exposure assignment, due to
reporting bias), selection bias and regression dilution bias [19].
Figure 2 illustrates how this concept is applied to inform causal
inference.
The analytic approach employed here for MR is the instru-
mental variable (IV) model, in which the genetic variant is treated
as an instrument which is assumed to be associated with the
disease only through its association with the intermediate
phenotype [18]. This requires firstly the identification of one or
more genetic variants (typically a single nucleotide polymorphism
or SNP) as the IV that is known from published data to be
associated with the phenotype [18]. The three key assumptions
underlying the MR approach are: a) the genotype is associated
with the phenotype; b) the genotype is independent of measured
and unmeasured confounders; and c) that the effect of genotype on
outcome is mediated only through the intermediate phenotype (no
pleiotropy) [17,18].
In this study, we set out to evaluate the relationship between
CRC, plasma 25-OHD levels and genotype at 4 genetic loci
tagging genes involved in vitamin D metabolism (Table S1) and
which have previously been shown to be associated with plasma
vitamin D levels in a pooled meta-analysis of Genome Wide
Association Studies [20]. In order to estimate whether there is a
causal relationship between plasma 25-OHD and CRC risk we
applied the control function IV estimator.
Methods
Ethics Statement
Ethical approval for the SOCCS study was obtained from the
MultiCentre Research Ethics committee for Scotland (reference
Figure 1. Vitamin D metabolic pathway.
doi:10.1371/journal.pone.0037662.g001
Figure 2. Directed acyclic graph (DAG) showing the instrumental variable assumptions underpinning our Mendelian randomisation
study (note the instrument is not allowed to have a direct effect on the outcome, hence this line is dashed). Instrumental variable
models use associations C and A to estimate the causal effect of a risk factor on an outcome (B).
doi:10.1371/journal.pone.0037662.g002
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Office of NHS Lothian (reference number 2003/W/GEN/05).
Study Population
We studied a subset of 2,001 cases and 2,237 controls from a
case-control study of CRC (Study Of Colorectal Cancer in
Scotland, SOCCS). We aimed to recruit all incident cases (1999–
2006) of adenocarcinoma of colorectum presenting to surgical
units in Scotland (18–79 years old). Exclusions were patient death
before ascertainment, patient too ill to participate, recurrent cases,
or patient unable to give informed consent due to learning
difficulties or other medical conditions. We recruited about 40% of
all incident cases in Scotland over the study period. During the
same period controls were drawn randomly from a population-
based register (community health index) and invited to participate.
Participation rates among those approached were approximately
58% for cases and an estimated 57% for controls. More than 99%
of the study participants were white Caucasian (see [21] for further
recruitment details).
The subjects completed one questionnaire with lifestyle and
cancer information and they were asked to report their status one
year prior diagnosis or recruitment, including information about
their general medical history, physical activity, smoking status,
intake of any regular intake of aspirin and NSAIDs, height, weight
and waist circumference were recorded. Additionally a semi-
quantitative food frequency questionnaire (Scottish Collaborative
Group FFQ, Version 6.41) was completed by participants (http://
www.foodfrequency.org), which consisted of 150 foods and the
individuals were asked to describe the amount and frequency of
each food on the list they have eaten a year prior to diagnosis or
recruitment. Further information about the questionnaires were
presented in detail previously [21]. In addition, each recruited
cancer subject was assigned an American Joint Committee on
Cancer (AJCC) stage derived from a synthesis of clinical,
pathological and imaging information [22]. Finally, for a subset
of the cancer cases (1,423, of those 1,376 with 25-OHD measured)
there was information about the symptoms they had developed
before recruitment. We grouped the cases into four categories: (1)
no symptoms (190 cases), (2) mild symptoms (290; including:
change in bowel habit, constipation, intermittent diarrhoea and
constipation, more frequent stools, diarrhoea, loose stools, excess
wind, mucus in stool and abdominal discomfort) and (3) severe
symptoms (220; including rectal bleeding, vomiting, weight loss,
loss of energy, loss of appetite and nausea) and (4) both, mild and
severe symptoms (676).
Family history risk was determined according to the Scottish
Executive cancer guidelines (http://www.sehd.scot.nhs.uk/), The
criteria for high family history risk of colorectal cancer are: 1) at
least three family members affected by colorectal cancer or at least
two with colorectal cancer and one with endometrial cancer in at
least two generations; one affected relative must be ,50 years old
at diagnosis and one of the relatives must be a first degree relative
of the other two; or 2) presence of the HNPCC syndrome; or 3)
untested first degree relatives of known gene carriers. The criteria
for moderate risk are: 1) one first degree relative affected by
colorectal cancer when aged ,45 years old; or 2) two affected first
degree relatives with one aged ,55 years old; or 3) three affected
relatives with colorectal or endometrial cancer, who are first
degree relatives of each other and one a first degree relative of the
consultant. Individuals that do not fulfil all the above criteria are
classified as low family history risk (Scottish Executive cancer
guidelines). For this analysis family history was coded as low vs.
medium/high family history of CRC.
Measurement of Plasma 25-OHD
The liquid chromatography-tandem mass spectrometry (LC-
MS/MS) method was used to measure 25-hydroxyvitamin D3 and
D2. This paper presents the 25-OHD (the total of 25-OHD2 and
25-OHD3); however, most of our samples contained no D2
(,3 ng/ml). The lower limit of detection with the LC-MS/MS
method was 4 ng/ml for D3 [23]. The LC MS/MS method was
performed following standard protocols and appropriate quality
control procedures (including multiple measurements of the same
sample from our cohort and standardization against standard
reference material, SRM 972) and it has been rated as the
preferred 25-OHD measurement method for population studies
by an international panel of experts [23]. More details about this
method can be found elsewhere [23,24]. For the analysis 25-OHD
measurements were standardized to remove the prominent effect
of the month when blood was taken on the 25-OHD concentra-
tion, as described in detail in Zgaga et al [3].
Genotyping Data
DNA samples were accurately quantified by Pico-GreenTM
and quality controlled prior to dispatch. Genotyping was
undertaken using TaqMan in the Wellcome Trust Clinical
Research Facility (WTCRF) in Edinburgh. 2,000 subjects for the
rs2282679 were genotyped as part of an array-based candidate
gene approach, using the Illumina Infinium I Custom array
platform and performed by Illumina (San Diego). Case and
control DNA samples were stored, genotyped and analysed in the
same way. In addition to avoid potential systematic batch-to-batch
variation or bias, samples were anonymised as to affection status
and were randomly distributed within plates. Data were subject to
Illumina or WTCRF quality control procedures. Assumptions of
Hardy-Weinberg Equilibrium (HWE) were tested using a chi-
squared test.
Statistical Analysis
The statistical package used was Stata version 11.0 (Stata Corp,
College Station, Texas). Participants were divided into quintiles
based on the combined distributions of cases and controls. Logistic
regression models were used to estimate the strength of association
between CRC risk and vitamin D plasma levels. The associations
were tested in three logistic regression models (crude model, model
I and model II). Model I was corrected for age and sex and Model
II was corrected for age, sex, Carstairs Deprivation Index, energy
(MJoules/day), smoking (non-smoker, former smoker and current
smoker), body mass index (BMI, kg/m
2, continuous), regular
NSAID intake (yes vs. no), family history (low vs. medium/high) of
cancer and physical activity (hours of cycling and other sports
activities, 4 groups). We also tested the association after sex, stage
of cancer at diagnosis (AJCC), presence of symptoms and time
between diagnosis and recruitment stratification. In addition the
association between CRC and rs2282679, rs12785878,
rs10741657 and rs6013897 was tested. Dataset for this analysis
was larger, and it comprised all SOCCS study participants for
whom genotyping of selected SNPs was successful (up to 5,449).
We also tested the interaction between genotype and vitamin D
plasma levels on CRC by comparing a model with and without an
interaction term between the two variables, using a likelihood ratio
test. Assumptions of Hardy-Weinberg Equilibrium were tested
using a chi-squared test.
To estimate the causal odds ratio we applied the control
function IV estimator for a 3-level categorical instrument Z coded
0, 1, 2 (SNP) a continuous intermediate phenotype X (plasma 25-
OHD3) and a binary outcome Y (CRC). The first stage of the
control function is a linear regression of the intermediate
Vitamin D and Colorectal Cancer
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values for the intermediate phenotype. The second stage is a
logistic regression of the outcome (Y) on the predicted values of the
intermediate phenotype including the estimated residuals from the
first-stage linear regression in the second-stage logistic regression
[25]. The rationale is that the first-stage residuals may be
correlated with unmeasured confounding factors. In addition to
a crude model, we also adjusted for age and sex. The strength of
the applied instruments were evaluated using the F statistics from
the first stage linear regression, with values lower than 10 taken as
evidence of a weak instrument [26]. Finally, we applied four
additional IV estimators which are presented and described in the
supplementary material (Methods S1).
Results
Levels of Plasma 25-OHD and CRC
Colorectal cancer risk was associated with lower levels of plasma
25-OHD in the crude model (Odds ratio (OR): 0.76, 95%
Confidence Interval (CI): 0.71, 0.81, p: 1.4610
214), after adjusting
for age and sex (OR: 0.75, 95% CI: 0.70, 0.81, p: 9.1610
215) and
after adjusting for age, sex, Carstairs Deprivation Index, energy,
smoking, BMI, regular NSAID intake, family history of cancer and
physical activity (OR: 0.75, 95% CI: 0.69, 0.81, p: 4.6610
212)
(Table 1). The 25-OHD CRC association was stronger for men
(crude model: OR: 0.68, 95% CI: 0.62, 0.75, p: 1.1610
213) than
women (crude model: OR: 0.84, 95% CI: 0.76, 0.93, p: 0.0009)
(Table S2). The 25-OHD CRC association was similar for early
(crude model: OR: 0.79, 95% CI: 0.72, 0.86, p: 2.0610
28) versus
late AJCC stage (crude model: OR: 0.74, 95% CI: 0.68, 0.80, p:
5.8610
212; Table S3). Furthermore, the 25-OHD CRC associ-
ation was weaker for those CRC patients that had no symptoms at
the time of the diagnosis (crude model: OR: 0.87, 95% CI: 0.73,
1.02, p: 0.09), when compared to those with mild (crude model:
OR: 0.80, 95% CI: 0.70, 0.91, p: 0.001) or severe symptoms
(crude model: OR: 0.78, 95% CI: 0.67, 0.90, p: 0.001; Table S4).
Finally, the 25-OHD CRC association was similar for those CRC
patients that were recruited soon after diagnosis (crude model:
OR: 0.77, 95% CI: 0.71, 0.83, p: 7.8610
25), when compared to
those who were recruited later (crude model: OR: 0.76, 95% CI:
0.70, 0.83, p: 1.3610
210; Table S5).
Genotype and Plasma 25-OHD Levels
There was no evidence for departure from HWE for all four
SNPs: rs2282679 p-value=0.25, rs12785878 p-value=0.78,
rs10741657 p-value=0.07 and rs6013897 p-value=0.52. The A
allele of rs2282679 and the T allele of rs12785878 were associated
with higher levels of plasma 25-OHD (Table 2). In particular, we
found that rs2282679 and rs12785878 genotypes were associated
with a decreased risk of 25-OHD deficiency defined as ,10 ng/ml
(rs2282679: for each A allele OR=0.88, 95% CI 0.80, 0.98,
p=0.02; rs12785878: for each T allele OR=0.89, 95% CI 0.79,
1.00, p=0.05; rs10741657; Table 2). These associations were not
different when we restricted the analysis only in the controls (data
not shown).
Genotype and CRC
Overall there was no evidence of an association between any of
the four SNPs and CRC risk (Table 3). When we stratified
according to plasma 25-OHD levels, the rs10741657 SNP was
associated with a decreased CRC risk for those of low plasma 25-
OHD levels (per A allele OR=0.88, 95% CI 0.75, 1.02, p=0.09)
and with an increased CRC risk for those of high plasma 25-OHD
levels (OR=1.12, 95% CI 0.98, 1.27, p=0.09), with a p-value of
interaction (p=0.05).
Before applying the MR approach we assessed the IV
assumptions. The first (that genotype is associated with the
phenotype) was fulfilled since we selected four SNPs that were
found to be linked to plasma 25-OHD levels in a pooled meta-
analysis of Genome Wide Association Studies [20]. The second
(genotype is independent of measured and unmeasured confound-
ers) was tested by investigating whether the instruments were
associated with any of the measured confounding factors that
might influence the relationship between plasma 25-OHD levels
and CRC (Table S6) and, as expected [27], there was no
evidence for an association between these confounding factors and
Table 1. Logistic regression analysis for the association between plasma 25-0HD on colorectal cancer risk.
N Crude model Model I* Model II
{
Standard logistic
regression analysis Cases Controls OR 95% CI p-value OR 95% CI p-value OR 95% CI p-value
25-OHD (continuous; ng/ml) 2001 2237 0.76 0.71, 0.81 1.4610
214 0.75 0.70, 0.81 9.13610
215 0.75 0.69, 0.81 4.6610
212
25-0HD (binary)
,10 ng/ml 973 826 1.00 1.00 1.00
$10 ng/ml 1028 1411 0.62 0.55, 0.70 1.2610
214 0.61 0.54, 0.69 7.1610
215 0.62 0.54, 0.72 6.1610
211
25-0HD (quintiles)
,5.31 486 366 1.00 1.00 1.00
5.31–9.39 461 425 0.82 0.68, 0.99 0.04 0.82 0.68, 0.99 0.04 0.75 0.61, 0.94 0.01
9.39–13.20 376 430 0.66 0.54, 0.80 ,0.0005 0.66 0.54, 0.80 ,0.0005 0.67 0.53, 0.83 ,0.0005
13.20–18.36 358 505 0.53 0.44, 0.65 ,0.0005 0.53 0.44, 0.64 ,0.0005 0.49 0.39, 0.61 ,0.0005
$18.36 320 511 0.47 0.39, 0.57 ,0.0005 0.46 0.38, 0.56 ,0.0005 0.45 0.35, 0.56 ,0.0005
p-value trend 2.2610
218 7.8610
219 3.6610
215
*Adjusted for age and sex.
{Adjusted for age, sex, Carstairs Deprivation Index, energy (MJoules/ day), smoking (non-smoker, former smoker and current smoker), body mass index (BMI, kg/m
2,
continuous), regular Non Steroidal Anti-Inflammatory Drug (NSAID) intake (yes vs. no), family history of cancer and physical activity (hours of cycling and other sports
activities, 4 groups).
doi:10.1371/journal.pone.0037662.t001
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outcome is mediated only through the intermediate phenotype)
was tested by interrogating of pleiotropic links of genes and SNPs
that we recently created [28]. For all SNPs there was no evidence
of pleiotropy and they were only found to be linked to plasma
vitamin D levels.
Using the rs2282679 as the IV, the estimated causal effect of
plasma 25-0HD on CRC risk was 0.94 (95% CI 0.49, 1.83), and
the F-statistic for the rs2282679 from the first stage of the IV
analysis was 15.80 in the age and sex adjusted analysis (Table 4).
Using the rs12785878 as the IV the causal effect was 1.23 (95% CI
0.60, 2.53), and the F-statistic for the rs12785878 from the first
stage of the IV analysis was 13.50 (Table 4). Using the
rs10741657 as the IV the causal effect was 0.89 (95% CI 0.40,
1.98), and the F-statistic for the rs10741657 from the first stage of
the IV analysis was 10.89 (Table 4). Finally, using the rs6013897
as the IV the causal effect was 0.99 (95% CI 0.40, 2.45), and the F-
statistic for the rs6013897 from the first stage of the IV analysis
was 0.98 (Table 4). The results of the other IV estimators are
presented in Tables S7, S8, S9, and S10.
Furthermore, we combined these four SNPs to form three allele
scores: 1) one allele score that combined all four SNPs, 2) an
upstream allele score that combined the SNPs rs12785878 and
rs10741657 and 3) a downstream allele score that combined the
SNPs rs2282679 and rs6013897. We then used this allele scores as
the IV. The causal effect for the overall allele score was 1.16 (95%
CI 0.60, 2.23; F-statistic 16.52), for the upstream allele score was
0.94 (95% CI 0.46, 1.91; F-statistic 7.87) and for the downstream
allele score was 0.93 (95% CI 0.53, 1.63; F-statistic 12.67)
(Table 4).
Discussion
Levels of Plasma 25-OHD and CRC
In this study, low levels of plasma 25-OHD were associated with
a higher risk of CRC in the whole sample and after stratification
for sex, tumour stage and severity of symptoms at presentation.
These results are in accordance with two recent meta-analyses of
serum or plasma prospective studies [14,29]. In addition a
systematic review and meta-analysis on colorectal adenoma
(CRA) showed a decreased risk with both incidence and
recurrence of CRA for an increase of 25-OHD by 20 ng/ml
[30]. However, a randomised clinical trial (RCT) (2686 average
risk subjects) found no effect of vitamin D supplementation and
incidence of CRC [31]. Similarly, a second RCT (Women’s
Health Initiative –WHI) investigating the effects of daily calcium
and vitamin D supplementation for seven years showed no effect
on CRC incidence among postmenopausal women [32]. Howev-
er, it should be noted that neither of these RCTs were designed
and powered for cancer as the primary outcome. In addition, re-
analysis of the WHI RCT found that concurrent oestrogen
therapy was an effect modifier of calcium and vitamin D
supplementation and for women that were not assigned to
oestrogen therapy calcium and vitamin D supplementation
decreased CRC risk [33]. Data from case-control and cohort
studies examining the associations between dietary vitamin D
intake and CRC are inconclusive [13].
Genotype, Plasma 25-OHD Levels and CRC
The A allele of rs2282679 and the T allele of rs12785878 were
associated with higher levels of plasma 25-OHD. These results are
Table 2. Association between plasma 25-0HD levels and rs2282679, rs12785878, rs10741657 and rs6013897.
25-0HD levels Crude model Model I*
Standard logistic regression
analysis ,10 ng/ml $10 ng/ml OR 95% CI p-value OR 95% CI p-value
rs2282679
CC 133 165 1.00 1.00
AC 698 905 0.96 0.75, 1.23 0.73 0.95 0.74, 1.22 0.69
AA 767 1163 0.82 0.64, 1.05 0.11 0.80 0.63, 1.03 0.09
per A allele 0.88 0.80, 0.98 0.02 0.87 0.79, 0.97 0.01
rs12785878
GG 72 66 1.00 1.00
TG 470 620 0.69 0.49, 0.99 0.04 0.69 0.48, 0.99 0.04
TT 980 1366 0.65 0.47, 0.93 0.02 0.65 0.46, 0.92 0.02
per T allele 0.89 0.79, 1.00 0.05 0.89 0.79, 1.00 0.05
rs10741657
GG 512 672 1.00 1.00
GA 385 925 0.97 0.84, 1.13 0.71 0.97 0.83, 1.13 0.71
AA 211 318 0.87 0.71, 1.07 0.19 0.88 0.71, 1.08 0.22
per A allele 0.94 0.84, 1.04 0.23 0.94 0.85, 1.04 0.25
rs6013897
AA 47 72 1.00 1.00
TA 470 599 1.20 0.82, 1.77 0.35 1.19 0.82, 1.75 0.39
TT 968 1319 1.12 0.77, 1.64 0.54 1.11 0.76, 1.62 0.60
per T allele 0.98 0.87, 1.11 0.73 0.98 0.86, 1.10 0.70
*Adjusted for age and sex.
doi:10.1371/journal.pone.0037662.t002
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Standard logistic
regression
analysis* Case/control status
Mean (SD) of
25-0HD (ng/ml) Crude model Model I
{
All-samples Cases Controls Cases Controls OR 95% CI p-value OR 95% CI p-value
rs2282679
CC 216 218 11.63 (7.45) 12.59 (8.45) 1.00 1.00
AC 1130 1160 11.01 (7.82) 13.29 (8.24) 0.98 0.80, 1.21 0.87 0.99 0.81, 1.21 0.92
AA 1325 1400 12.00 (7.86) 14.01 (8.65) 0.96 0.78, 1.17 0.66 0.96 0.78, 1.17 0.68
per A allele 0.97 0.90, 1.06 0.55 0.97 0.90, 1.06 0.55
rs12785878
GG 81 112 9.16 (7.29) 10.67 (7.11) 1.00 1.00
TG 749 798 10.89 (7.50) 13.50 (8.20) 1.30 0.96, 1.76 0.09 1.30 0.96, 1.76 0.09
TT 1667 1713 11.69 (7.72) 13.59 (8.59) 1.35 1.00, 1.80 0.05 1.35 1.00, 1.81 0.05
per T allele 1.08 0.98, 1.20 0.11 1.08 0.98, 1.20 0.11
rs10741657
GG 851 855 11.15 (7.58) 13.82 (8.88) 1.00 1.00
GA 1082 1201 11.54 (7.88) 13.19 (8.25) 0.91 0.80, 1.03 0.12 0.90 0.79, 1.02 0.11
AA 402 371 11.82 (7.62) 13.78 (8.51) 1.09 0.92, 1.29 0.33 1.08 0.91, 1.29 0.35
per A allele 1.01 0.94, 1.10 0.72 1.01 0.93, 1.10 0.77
rs6013897
AA 92 83 12.44 (8.83) 13.89 (11.98) 1.00 1.00
TA 739 806 11.45 (7.29) 12.84 (8.44) 0.83 0.60, 1.13 0.24 0.84 0.61, 1.15 0.27
TT 1615 1648 11.32 (7.83) 13.72 (8.34) 0.88 0.65, 1.20 0.43 0.90 0.66, 1.21 0.48
per T allele 1.02 0.92, 1.13 0.71 1.02 0.92, 1.13 0.68
Allele score 2815 2924 1.00 0.97, 1.04 0.87 1.01 0.97, 1.04 0.69
‘‘Synthesis’’ allele score 2630 2761 1.04 0.98, 1.10 0.17 1.04 0.99, 1.10 0.14
‘‘Metabolism’’ allele
score
2779 2884 0.99 0.94, 1.05 0.79 0.99 0.94, 1.05 0.82
,10ng/ml 25-0HD
levels
Cases Controls OR 95% CI p-value OR 95% CI p-value
rs2282679
CC 66 67 6.01 (2.84) 5.71 (3.05) 1.00 1.00
AC 392 306 5.21 (2.90) 5.54 (2.97) 1.30 0.90, 1.89 0.17 1.29 0.89, 1.88 0.17
AA 399 368 5.47 (2.78) 5.81 (2.79) 1.10 0.76, 1.59 0.61 1.10 0.76, 1.59 0.61
per A allele 0.96 0.82, 1.12 0.58 0.96 0.82, 1.12 0.60
rs12785878
GG 32 40 3.98 (2.79) 5.18 (3.12) 1.00 1.00
TG 249 221 5.37 (2.87) 5.88 (2.81) 1.41 0.86, 2.32 0.18 1.41 0.86, 2.32 1.18
TT 526 454 5.52 (2.83) 5.66 (2.90) 1.45 0.89, 2.34 0.13 1.46 0.90, 2.36 0.13
per T allele 1.10 0.93, 1.31 0.27 1.11 0.93, 1.32 0.25
rs10741657
GG 296 216 5.55 (2.84) 5.60 (2.99) 1.00 1.00
GA 346 339 5.45 (2.81) 5.74 (2.85) 0.74 0.59, 0.94 0.01 0.74 0.59, 0.94 0.01
AA 113 98 5.11 (2.73) 5.61 (2.79) 0.84 0.61, 1.16 0.29 0.84 0.61, 1.17 0.31
per A allele 0.88 0.75, 1.02 0.09 0.88 0.75, 1.02 0.10
rs6013897
AA 23 24 5.00 (2.62) 4.55 (2.71) 1.00 1.00
TA 237 233 5.66 (2.74) 5.36 (3.06) 1.06 0.58, 1.93 0.85 1.07 0.59, 1.96 0.82
TT 531 437 5.35 (2.84) 5.88 (2.78) 1.27 0.71, 2.28 0.43 1.29 0.72, 2.31 0.40
per T allele 1.17 0.97, 1.41 0.10 1.18 0.98, 1.42 0.09
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vitamin D deficiency [20]. The rs2282679 SNP is located in the
GC gene, which encodes a vitamin D binding protein that binds
and transports vitamin D (Figure 1) [20]. The rs12785878 SNP is
located in the DHCR7 gene that encodes the enzyme 7-
dehydrocholesterol (7-DHC) reductase, which converts 7-DHC
to cholesterol. 7-DHC is a precursor of vitamin D3. Mutations in
the DHCR7 may lead to a decreased activity of the 7-DHC
reductase and therefore to high levels of 7-DHC and vitamin D3
(Figure 1) [20]. However the other two SNPs (rs10741657,
rs6013897) that were also found to be strongly associated with
vitamin D levels in the vitamin D genome wide association study
were not associated with vitamin D status in our cohort.
rs10741657 is located in the CYP2R1 gene, which encodes an
enzyme thought to be involved in the 25-hydroxylation of vitamin
D3 to 25(OHD) [20]. rs6013897 is located in the CYP24A1 gene,
which encodes an enzyme that initiates the degradation of
1,25(OH)2D [20]. The evidence for the role of the enzymes coded
by CYP2R1and CYP24A1 is limited and not replicated in other
candidate studies [20].
None of the four SNPs were associated with CRC risk, although
we found an interaction between 25-OHD levels and rs10741657.
The results of the MR analysis did not support a causal
relationship between plasma 25-OHD and CRC risk. Although
not significant, the inverse relationship was noted when rs2282679
or rs10741657 were used as instrument, but not when rs12785878
or rs6013897. The results remained inconsistent when the three
allele scores of the four SNPs was used. The fact that the inverse
association that was observed when we applied the conventional
epidemiological methods was not replicated when the MR
approach was used might be due to several reasons. It is possible
that unmeasured or latent variables confounded the associations
and there is no true effect of vitamin D on CRC. An alternative
explanation is that there might be reverse causality between
vitamin D and CRC, given that the plasma of the cases was
collected after diagnosis: it cannot be excluded that low plasma 25-
OHD is the consequence of disease or a result of patients being
bedbound and lacking the exposure to sun. However, when we
looked at cases with very mild or no symptoms or cases at the very
early stages of the disease we still observed an inverse association
between 25-OHD levels and CRC. In addition, given the
biological potential of vitamin D having a causal link with cancer,
factors that affect the performance of the IV estimators might also
explain these findings.
Major limitations of conventional instrumental variable ap-
proaches result from the strict assumptions that need to be satisfied
for method to be reliable. It is true that genotype is associated with
phenotype, however, SNPs that have been used as instruments are
only weakly associated to phenotype and explain only a small
portion of trait variance. While we tested for common confound-
ers, it is possible that hidden confounding from unmeasured
variables affects the analysis. While we see no association between
genotype and the outcome, weaker pleiotropic links cannot be
excluded with certainty.
Table 3. Cont.
Standard logistic
regression
analysis* Case/control status
Mean (SD) of
25-0HD (ng/ml) Crude model Model I
{
All-samples Cases Controls Cases Controls OR 95% CI p-value OR 95% CI p-value
$10 ng/ml 25-0HD
levels
Cases Controls OR 95% CI p-value OR 95% CI p-value
rs2282679
CC 69 96 17.01 (6.46) 17.34 (7.68) 1.00 1.00
AC 380 525 17.00 (6.71) 17.80 (6.86) 1.01 0.72, 1.41 0.97 1.01 0.72, 1.42 0.94
AA 487 676 17.35 (6.53) 18.48 (7.40) 1.00 0.72, 1.39 0.99 1.00 0.72, 1.39 0.99
per A allele 1.00 0.87, 1.14 0.98 0.99 0.87, 1.14 0.93
rs12785878
GG 23 43 16.36 (5.11) 15.78 (5.86) 1.00 1.00
TG 246 374 16.47 (6.55) 18.00 (6.91) 1.23 0.72, 2.09 0.45 1.24 0.73, 2.11 0.43
TT 584 782 17.24 (6.41) 18.21 (7.34) 1.40 0.83, 2.34 0.21 1.40 0.83, 2.35 0.20
per T allele 1.15 0.98, 1.35 0.09 1.15 0.98, 1.35 0.09
rs10741657
GG 271 401 17.27 (6.30) 18.26 (7.78) 1.00 1.00
GA 383 542 17.04 (6.87) 17.85 (7.00) 1.05 0.85, 1.28 0.67 1.04 0.85, 1.27 0.70
AA 148 170 16.94 (5.99) 18.50 (6.98) 1.29 0.98, 1.69 0.07 1.28 0.98, 1.68 0.07
per A allele 1.12 0.98, 1.27 0.09 1.11 0.98, 1.27 0.10
rs6013897
AA 35 37 17.33 (8.01) 19.95 (11.77) 1.00 1.00
TA 249 350 16.96 (5.86) 17.82 (7.09) 0.75 0.46, 1.23 0.25 0.76 0.47, 1.24 0.28
TT 545 774 17.13 (6.69) 18.15 (7.07) 0.74 0.46, 1.20 0.22 0.75 0.47, 1.21 0.24
per T allele 0.94 0.80, 1.10 0.44 0.94 0.80, 1.10 0.44
doi:10.1371/journal.pone.0037662.t003
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methods for assessing causality between 25-OHD concentrations
and CRC, based on the platform for the Bayesian analysis of
complex statistical models using Markov chain Monte Carlo
methods. This method improves on the classical Mendelian
Randomisation approach as it allows for pleiotropic links between
components of the model, enables easy inclusion of other
covariates and does not depend as much on the strength of the
instruments.
The wide application of the genome wide association studies
(GWAS), has allowed for the MR studies to become more
feasible now, as common SNPs linked to various intermediate
phenotypes have been identified [34]. To date in 2011, several
applied MR studies were published investigating causal rela-
tionships in a wide range of diseases including cancer [35],
coronary heart disease [36,37], diabetes [38,39], mental
disorders[40–42], lung function [43] and other diseases
[44,45]. Some of these studies replicated the results of the
conventional epidemiological methods and confirmed causality
(or no causality) of the intermediate phenotype on the outcome
[40,44,45]. One of the main reasons behind this lack of
replication is the fact that the genetic instruments that are
employed are generally weak and therefore the power of the MR
studies will be inadequate [34].
According to a recent study on the power and sample size
requirements of MR studies based on the strength of the
instruments, found that MR studies will require large (n.1000)
and often very large (n.10000) sample sizes to draw causal
conclusions that are statistically significant [34]. Based on their
findings from simulated analyses most of the published MR
studies are under-powered (see Table S11 for a review of the
11 MR studies published in 2011). Using simulations presented
in the paper of Pierce et al [34] and accounting for sample size,
strength of the employed instruments and observed effect size,
we estimate that the sample size in this study gave power of
,0.35.
Conclusion
This study shows that higher plasma 25-OHD levels are
associated with a lower CRC risk, a finding that is consistent
with recent meta-analyses of prospective studies. However, this
finding was not replicated when the MR approach was
employed. This finding might be due to a lack of a true effect
of vitamin D on CRC or due to reverse causation. It may also be
due to weak instruments and limited statistical power. The lack
of power is a common characteristic of many MR studies and
therefore a careful selection of instruments plus an adequate
sample size are deemed necessary for this method to be able to
make causal conclusions. Given the extent of vitamin D
deficiency among individuals living in high latitudes, a large
consortium of similar vitamin D and CRC studies and/or the
application of alternative methods that are less sensitive to weak
instrument bias [46] are necessary to refine the effect of vitamin
D on CRC cancer and other chronic diseases.
Table 4. Control function instrumental variable estimator of the causal odds ratio for the effect of plasma 25(0H)D on colorectal
cancer risk.
Model plasma 25-0HD (continuous, ng/ml)
rs2282679 OR 95% CI F statistic
Unadjusted 0.58 0.11, 3.10 7.29
Adjusted for age and sex 0.94 0.49, 1.83 15.80
rs12785878
Unadjusted 4.03 0.93, 17.41 9.70
Adjusted for age and sex 1.23 0.60, 2.53 13.50
rs10741657
Unadjusted 1.15 0.00, 762.13 0.49
Adjusted for age and sex 0.89 0.40, 1.98 10.89
rs6013897
Unadjusted 2.26 0.06, 86.31 1.58
Adjusted for age and sex 0.99 0.40, 2.45 0.98
Allele score
*
Unadjusted 1.50 0.42, 5.35 12.95
Adjusted for age and sex 1.16 0.60, 2.23 16.52
Allele score (upstream)
{
Unadjusted 1.83 0.22, 15.19 4.63
Adjusted for age and sex 0.94 0.46, 1.91 7.87
Allele score (downstream)
{
Unadjusted 0.83 0.34, 2.05 14.89
Adjusted for age and sex 0.93 0.53, 1.63 12.67
*Allele score that combines all 4 SNPs: rs12785878, rs10741657, rs2282679 and rs6013897.
{Allele score that combines 2 upstream (synthesis) SNPs: rs12785878, rs10741657.
{Allele score that combines 2 ‘‘metabolism’’ SNPs: rs2282679 and rs6013897.
doi:10.1371/journal.pone.0037662.t004
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